<DOC>
	<DOCNO>NCT01362478</DOCNO>
	<brief_summary>Schizophrenia disable mental disease affect 1 % worldwide population . There overall heritability estimate 68 % underlying liability schizophrenia . Molecular epigenetic study overcome complexity traditional genetic study provide new framework search etiological factor schizophrenia . DNA methylation provide example epigenetic process affect gene expression . Several postmortem experiment find increase DNA methylation glutamic acid decarboxylase ( GAD67 ) reelin promoter , hypomethylation membrane-bound catechol-O-methyltransferase ( MB-COMT ) promoter gene prefrontal cortex schizophrenia patient . Because impossible obtain brain tissue schizophrenia patient clinically , peripheral blood mononuclear cell ( PBMC ) partly represent brain gene expression . It report use PBMC biomarkers epigenetic abnormality , histone acetylation methylation , schizophrenia . To investigator best knowledge , gene promoter DNA methylation abnormality schizophrenia limited postmortem study . It warrant study DNA methylation use schizophrenia 's PBMC . Recently , endophenotype strategy emerge important tool understanding genetic architecture schizophrenia . Some cognitive function , attention work memory ( WM ) , use candidate endophenotypes genetic study schizophrenia . Synchronized GABA neurotransmission dorsolateral prefrontal cortex require adequate attention work memory , suggest impairment GABA-mediated inhibition prefrontal cortex could contribute endophenotype presentation schizophrenia .</brief_summary>
	<brief_title>Gene Promoter DNA Methylations Their Relationships With Endophenotypes Patients With Schizophrenia</brief_title>
	<detailed_description>The study approve Institutional Review Board participate institution recruit patient . We recruit 60 patient schizophrenia 60 healthy control subject explain study goal get informed consent . We evaluate performance continuous performance test ( CPT ) work memory subset Chinese version WAIS-III case control subject . We assay reelin , GAD , MB-COMT gene promoter DNA methylation use methylation specific PCR ( MSP ) quantify gene expression use quantitative reverse transcription polymerase chain reaction ( qRT-PCR ) . Patients follow one year receive evaluation .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Case age 2065 yearold fulfill DSMIV criterion schizophrenia patient pregnant significant medical condition unstable psychiatric feature ( e.g . suicidal ) , agitation history substance abuse drug addiction within previous 6 month , exception nicotine dependence . Control 2065 yearold major psychiatric disorder , schizophrenia , mood disorder , substance use disorder , except nicotine family history schizophrenia , mood disorder , substance use disorder serious medical condition</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>schizophrenia</keyword>
	<keyword>gene promoter</keyword>
	<keyword>methylation</keyword>
	<keyword>endophenotype</keyword>
	<keyword>epigenetic</keyword>
</DOC>